Nilemdo (Bempedoic Acid)

Bempedoic Acid, the active ingredient in Nilemdo, is an ATP citrate lyase inhibitor presented as an oral tablet for oral use. It is used to lower low‑density lipoprotein cholesterol in adults with primary hypercholesterolemia or heterozygous familial hypercholesterolemia, typically as an adjunct to statin therapy.

GNH USA supplies Nilemdo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Delivery is coordinated globally with experienced logistics teams.

Nilemdo is indicated for lipid‑lowering therapy in patients with elevated LDL‑cholesterol.

- Primary hypercholesterolemia: reduces LDL‑cholesterol levels when added to statin therapy in adults. - Heterozygous familial hypercholesterolemia: lowers LDL‑cholesterol as an adjunct to existing lipid‑lowering regimen. - Elevated LDL‑cholesterol not at target: contributes to achieving LDL‑C goals when combined with statins.

Adverse reactions have been reported with Nilemdo.

Common Side Effects: - Upper respiratory tract infection - Musculoskeletal pain, including back pain - Elevated serum uric acid (gout) - Mild increases in liver enzymes - Diarrhoea

Serious or Rare Side Effects: - Tendon rupture - Severe hypersensitivity reactions (e.g., angio‑edema) - Rhabdomyolysis - Acute liver failure - Severe allergic dermatitis

Before initiating Nilemdo, clinicians should consider several safety aspects. - Renal function: assess baseline kidney function and monitor periodically. - Hepatic function: check liver enzymes prior to treatment and during therapy. - Pregnancy: safety unknown; avoid use unless potential benefit outweighs risk. - Drug interactions: review concomitant lipid‑lowering agents and other medications. - Monitoring: measure LDL‑C levels regularly to evaluate efficacy. - Store at ambient temperature: keep in the original pack, protect from moisture.

Nilemdo may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole): may increase bempedoic acid exposure. - Bile acid sequestrants: can reduce oral absorption of the drug. - Fibrates combined with statins: heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Niacin or ezetimibe: monitor lipid parameters for additive effects. - Warfarin: observe INR values for potential changes. - Antihypertensive agents: no significant interaction, but monitor blood pressure as needed.